Abstract
Introduction:
Hip exoskeletons can lower the metabolic cost of walking in many tasks and populations, but their assistance patterns must be tailored to each user. We developed a simulation-based, human-in-the-loop (HIL) optimization framework combining machine learning (ML) and global optimization to personalize hip exoskeleton assistance patterns.
Methods:
Using data from ten healthy adults, we trained a Gradient Boosting (GB) surrogate model to predict normalized metabolic cost as a function of Peak Magnitude and End Timing of assistive torque. GB achieved the lowest relative absolute error percentage (RAEP) of 0.66%, outperforming Random Forest (RAEP = 0.83%) and Support Vector Regression (RAEP = 0.98%) among nine ML models. We then evaluated seven optimization algorithms, including Covariance Matrix Adaptation Evolution Strategy, Bayesian Optimization, Exploitative Bayesian Optimization, Cross-Entropy, Genetic Algorithm, Gravitational Search Algorithm (GSA), and Particle Swarm Optimization (PSO), to identify optimal assistance profiles.
Results:
GSA predicted the lowest metabolic cost (−1.06), equivalent to an estimated 53% reduction relative to no exoskeleton assistance, while PSO showed the highest efficiency (AUC = 0.24).
Discussion:
These simulated predictions, though not empirical measurements, demonstrate the framework’s ability to streamline algorithm selection, reduce experimental burden, and accelerate translation of exoskeleton optimization into rehabilitation, occupational, and performance enhancement applications with broader biomechanical and clinical impact.
1 Introduction
Mobility disability affects over 26.9% of older adults worldwide (), contributing to reduced independence, increased healthcare costs, and reduced quality of life (). Wearable robotic assistive devices, such as lower-limb exoskeletons, have emerged as promising tools for improving walking efficiency by reducing the energetic cost of walking (Shepertycky et al., 2021), providing physical support (; ), and restoring weak limb function (). Elevated metabolic cost during walking is a common issue among older adults and individuals with neuromuscular or vascular impairments, often leading to early fatigue, reduced mobility, and a greater risk of sedentary behavior, further exacerbating functional decline and health complications (; ; ; ). Despite considerable success in laboratory experiments, many exoskeletons have shown limited benefits in real-world applications due to the inherent complexity of human-robot interaction and challenges related to portability and practical deployment outside controlled environments (; ; ; ). Because the hip can generate substantial positive torque during daily activities, optimally tuned hip exoskeletons have the potential to reduce metabolic cost by up to 40% (; ; Seth et al., 2018; ; ; ). However, personalized tuning is necessary to maximize the benefits of the exoskeleton and human performance, which is challenging outside of a laboratory (Zhang et al., 2017; Slade et al., 2022; ).
Human-in-the-loop (HIL) optimization has been developed as a method for real-time personalization of exoskeleton parameters. The structure of this HIL optimization strategy is shown in the upper (red) loop of Figure 1, where human feedback is used to adjust assistance parameters systematically. In this process, device control is iteratively adjusted to enhance user performance based on physiological feedback during real-time use (; ; ; ; ; ). HIL optimization has substantially improved exoskeleton performance across various activities, including recent translation into real-world conditions (; ; Sreenivasa et al., 2017; Zhang et al., 2017). However, assessing key performance metrics such as metabolic rate often involves costly equipment and prolonged steady-state walking, making these experiments challenging (; ; ). To get around these challenges, simulation methods using surrogate models have become more common. These models approximate the relationship between assistance parameters and physiological outcomes using Machine Learning (ML) techniques trained on experimental data (). Once validated, surrogate models enable rapid and cost-effective testing of numerous assistance parameter combinations within the simulation framework, eliminating the need for additional human trials. The lower (blue) loop in Figure 1 outlines this surrogate-based optimization framework, where ML predictions guide iterative parameter refinement without requiring direct physiological measurements. Recent studies used data-driven methods to estimate within-stride metabolic cost during walking (; ; ; ; ). They showed that variations in biomechanical variables can predict energy expenditure with high temporal resolution and greater consistency compared to earlier model-based approaches (; ; ; ; ). Although these models cannot fully capture the complexities of human adaptation, they offer meaningful insights into parameter sensitivity and can guide experimental design.
FIGURE 1
Complementing data-driven methods, biomechanics-based optimization approaches have leveraged musculoskeletal modeling and control theory to design torque profiles that minimize joint loads and enhance gait stability (
Recent research highlights the effectiveness of ML-based approaches in various exoskeleton applications. Kutulakos and Slade (
The present study introduces a surrogate-based optimization framework for hip exoskeleton assistance (
2 Methods
2.1 Experimental data
This study utilized a previously published dataset collected during treadmill walking with a bilateral semi-rigid hip exoskeleton designed to assist hip extension through torque application during early stance (
Twelve walking conditions were tested, consisting of ten powered assistance profiles, one PowerOff condition (with the exoskeleton worn but not actuated), and one NoExo condition (without the device) (
This study utilized an existing dataset collected from 10 healthy adults during a previously approved experimental protocol (
2.2 Simulated methods
Experimental walking data from a previous study involving ten healthy adults were used to train multiple ML models to predict normalized metabolic cost (
Although metabolic landscapes were simulated, they were directly trained on experimental data from 10 healthy adults. The surrogate model was therefore not arbitrary but grounded in real measurements, serving as a computational approximation of user feedback. This framework enabled controlled benchmarking of optimization algorithms while avoiding the burden of repeated long-duration experiments. Importantly, in real-world HIL optimization, algorithms would operate with live user feedback, whereas the surrogate provides a reproducible and safe environment for preliminary evaluation.
Although individual metabolic landscapes are known to vary due to physiological and neuromuscular differences, this study pooled data across 10 healthy subjects to train a population-level surrogate model. The intention was not to create a fully personalized model for each subject but to capture generalizable trends in the relationship between assistance parameters and metabolic cost. This surrogate served as a representative user feedback model, enabling simulation-based evaluation of various optimization algorithms in a controlled environment. The study’s main goal was to determine which optimization strategy is most effective for human-in-the-loop exoskeleton parameter tuning. In future real-time applications, the selected algorithm will be applied directly to honest user feedback to personalize assistance. At the same time, the surrogate model will remain a simulation tool for preliminary exploration.
The chosen models cover a spectrum of learning approaches, including linear (LR, PR), non-parametric (GP), and ensemble-based (GB, RF), to thoroughly explore the metabolic cost profile. These surrogates were integrated with seven global optimization algorithms to evaluate their ability to identify low-cost assistance profiles. Covariance Matrix Adaptation Evolution Strategy (CMAES) is a generative, model-free, and sample-efficient local optimizer that adapts its search distribution based on the best-performing parameter sets in each generation, making it effective for noisy and non-convex problems (
TABLE 1
| # | Machine learning models | Optimization algorithms |
|---|---|---|
| 1 | Linear Ridge (LR) | Covariance Matrix Adaptation Evolution Strategy (CMAES) |
| 2 | Polynomial Ridge (PR) | Bayesian Optimization (BO) |
| 3 | Support Vector Regression (SVR) | Exploitative Bayesian Optimization (EBO) |
| 4 | Random Forest (RF) | Cross-Entropy Method (CE) |
| 5 | Gradient Boosting (GB) | Genetic Algorithm (GA) |
| 6 | Gaussian Process – Absolute Exponential (GPAE) | Gravitational Search Algorithm (GSA) |
| 7 | Gaussian Process – Matern 3/2 (GPM) | Particle Swarm Optimization (PSO) |
| 8 | Gaussian Process – Rational Quadratic (GPRQ) | |
| 9 | Gaussian Process – Squared Exponential (GPSE) |
Machine learning models and global optimization algorithms. The listed models were used to construct surrogate predictors of metabolic cost, while the optimization algorithms were applied to identify low-cost assistance parameters based on the surrogate models.
2.3 Data augmentation
A simplified biomechanical representation of hip assistance was created, modeling the exoskeleton torque profile as a piecewise semi-linear function (
To improve model robustness, 20 augmented samples were generated for each of the 100 experimental trials by adding zero-mean Gaussian noise (σ = 0.05, ∼4.6% of the normalized range) to the input parameters (Peak Magnitude and End Timing). This produced 2000 synthetic trials in total. Unlike prior work that perturbed metabolic cost to simulate measurement noise (
For each experimental trial, inspired by (
2.4 Data preparation and normalization
The combined dataset consisted of 100 valid experimental trials and 200 synthetic trials, totaling 300 samples. This augmentation enhanced the surrogate model’s generalization ability across diverse assistance profiles (
2.5 Machine learning (ML) model: training and hyperparameters
Additional polynomial terms (e.g., squared features) were included for PR to capture potential nonlinear interactions. The resulting feature matrix and target vector were used for training and evaluating all surrogate models (
Model-specific configurations included the use of L2 regularization (λ = 1) for both LR and PR (
Similar to the literature (Slade et al., 2022;
Recent advances in deep stable learning for handling imbalanced datasets (Xu et al., 2025) provide additional methodological support for our surrogate modeling strategy. While their application focused on fault diagnosis in engineering systems, the underlying principles of improving robustness and predictive reliability are directly transferable to biomechanical optimization, where data heterogeneity and limited sample sizes often present similar challenges.
To prevent overfitting, we employed repeated 5-fold cross-validation (500 iterations), regularization where available, and constrained model complexity (e.g., limiting GB tree depth). These measures improved generalizability and reduced the risk of models capturing noise rather than meaningful trends (Slade et al., 2022;
2.6 Model evaluation
Model performance was evaluated using Relative Absolute Error (RAE) and Relative Absolute Error Percentage (RAEP) across the 100 × 5-fold cross-validation scheme. For each test sample , the relative absolute error and RAEP(%) were calculated as shown in Equations 2, 3:where and are the ground-truth and predicted normalized metabolic cost for the trial, respectively, and is the number of test samples per split. RAEP reflects the average percentage deviation from actual values, normalized to ground truth, and allows for consistent model comparison regardless of cost magnitude. The distributions of RAEP across all 500 splits were aggregated and visualized to assess each model’s accuracy and robustness. Models with lower RAEP and more concentrated error distributions were considered superior in terms of generalization and suitability for use in surrogate-based optimization.
2.7 Optimization and hyperparameters
The most accurate surrogate model will simulate the metabolic landscape with the highest accuracy and guide parameter optimization. Seven global optimization algorithms—CMAES, BO, EBO, CE, GA, GSA, and PSO—were implemented to identify assistance parameters (Peak Magnitude and End Timing) that minimized predicted metabolic cost. Each optimization algorithm was executed across 10 independent trials (re-running 10 times) to ensure robustness against stochastic variability in initialization and search trajectory, with 200 evaluations per trial (a total of 10 × 200 evaluations) to reflect a realistic limit on experimental feasibility in HIL studies (
CMAES was initialized with a population size of 15, a mean vector of (0.5, 0.5), and a step-size (σ) of 0.3, using an elite size of 3 to guide distribution adaptation (
Similar to sustainability-driven optimization in other engineering domains, such as additive manufacturing (
To ensure comparability across optimization algorithms, all methods were initialized using consistent strategies, supported by setting a fixed random seed (rng (42)) for reproducibility. CMAES and CE began with a mean vector of (0.5, 0.5) and a standard deviation (σ) of 0.3. BO and EBO used normalized input bounds with fixed exploration constants of 2.6 and 0.93, respectively. GA, GSA, and PSO initialized their populations (or particles/agents) uniformly across the normalized parameter space [0, 1]2 using identical seeds. These design choices reduced initialization bias, ensuring that differences in performance arose from algorithm dynamics rather than initial sampling variance. All optimization parameters and configurations are summarized in Table 2 and detailed further in the supplementary code repository.
TABLE 2
| Algorithm | Population Size/Agents | Initialization Mean/Method | Key parameters | Random seed used |
|---|---|---|---|---|
| CMA-ES | 15 | Mean: (0.5, 0.5) σ = 0.3 | λ = 15 Elite size = 3 | rng (42) |
| Bayesian Optimization (BO) | N/A (sequential) | Uniform sampling in [0, 1]2 | Acquisition: EI+ Exploration constant = 2.6 | rng (42) |
| Exploitative BO (EBO) | N/A (sequential) | Uniform sampling in [0, 1]2 | Acquisition: EI+ Exploration constant = 0.93 | rng (42) |
| Cross-Entropy (CE) | 15 | Mean: (0.5, 0.5) σ = 0.3 | Elite fraction = 0.5 λ = 30 (2× CMAES) | rng (42) |
| Genetic Algorithm (GA) | 20 | Uniform sampling in [0, 1]2 | Crossover fraction = 0.8 Generations = ceil (200/20) | rng (42) |
| Gravitational Search Algorithm (GSA) | 20 | Uniform sampling in [0, 1]2 | G0 = 100; α = 20 Max iterations = ceil (200/20) | rng (42) |
| Particle Swarm Optimization (PSO) | 20 | Uniform sampling in [0, 1]2 | Inertia-based updates Swarm size = 20; Iterations = ceil (200/20) | rng (42) |
Summary of optimization algorithm configurations and initialization settings. All algorithms operated within normalized bounds [0, 1] for both Peak Magnitude and End Timings. The maximum number of function evaluations was set to 200 per run for all methods.
2.8 Performance metrics
Optimization algorithm performance was evaluated using two complementary metrics: Area Under the Curve (AUC) and Average Rate of Improvement (ARI) (
On the other hand, ARI quantifies the average per-iteration improvement in cost by computing the mean absolute reduction in the best-found value between consecutive evaluations (
In general, represents the number of evaluations in a given optimization run, which can vary if an optimizer terminates early. In this study, however, we fixed for all algorithms to maintain identical evaluation budgets and enable fair comparisons across optimizers. These metrics—adapted from best practices in benchmarking optimization algorithms (
ARI and AUC are particularly suited for assessing algorithm suitability as exoskeleton parameter tuning, where convergence speed and consistency affect user comfort, time efficiency, and clinical feasibility (
3 Results
3.1 Model performance
Figure 2 displays the RAEP distributions for each of the nine surrogate models across all cross-validation splits. GB achieved the lowest RAEP (0.66%) among all models, indicating the highest predictive accuracy. This model also exhibited greater variability in distribution, likely due to its responsiveness to localized error reduction. RF followed with an RAEP of 0.83%, outperforming all linear models and kernel-based methods. In contrast, SVR showed the poorest performance with an RAEP of 0.98%, reflecting challenges in capturing the nonlinearities and variations of the metabolic cost surface. All four GP models—GPSE, GPM, GPAE, and GPRQ—and the LR and PR models produced nearly identical RAEP values of 0.88%. These results suggest that while GP models provided smooth and stable estimates, they did not outperform tree-based ensembles in this dataset. LR and PR also failed to achieve an acceptable accuracy, likely due to their limited ability to model variations and nonlinear interactions in the metabolic cost time profile. The boxplots reveal that while GB delivered the lowest median and mean RAEP, it also had a broader interquartile range, reflecting higher sensitivity to data distribution and outliers. This trade-off suggests that GB offers the most flexible and accurate surrogate for capturing complex cost patterns, at the expense of higher variability in certain conditions.
FIGURE 2

Comparison of surrogate model performance based on Relative Absolute Error Percentage (RAEP). Boxplots show RAEP distributions across all cross-validation splits for nine machine learning models: Linear Ridge (LR), Polynomial Ridge (PR), four Gaussian Process (GP) variants—Squared Exponential (GPSE), Matern 3/2 (GPM), Absolute Exponential (GPAE), and Rational Quadratic (GPRQ)—Support Vector Regression (SVR), Random Forest (RF), and Gradient Boosting (GB). GB achieved the lowest RAEP (0.66%) with greater variability, indicating high accuracy with some sensitivity to data distribution. SVR had the highest error (0.98%), while GP models and linear methods showed similar intermediate performance (0.88%). RF (0.83%) performed better than most but did not surpass GB. The solid black line in each boxplot represents the median RAEP value, and the dashed black line denotes the mean. While RAEP indicates that all models achieve relatively low average errors across cross-validation splits, this metric reflects generalizability on test sets and does not capture trial-specific deviations or nonlinear dynamics.
Figure 3 illustrates the trial-wise comparison of actual versus predicted normalized metabolic cost across the complete dataset for each surrogate model. Among all models, GB (Figure 3I) demonstrated the highest alignment between predicted and actual trends, closely tracking the full dynamic range of trial-level metabolic responses. The model captured peaks and valleys with minimal lag, reflecting its strong temporal fidelity and low overall RAEP. RF (Figure 3H) and the GP models—GPSE, GPM, GPAE, and GPRQ (Figures 3C–F)—showed moderate agreement with actual values but exhibited some smoothing, particularly in capturing rapid fluctuations. While they followed general trends, their predictions tended to underestimate trial-to-trial variability. Linear models LR and PR (Figures 3A,B) showed the weakest performance, failing to capture significant inflection points and producing flat or lagged predictions. SVR (Figure 3G) struggled particularly in low-cost regions, displaying more frequent divergence from the ground truth. These differences highlight the limitations of models that lack the expressive capacity needed to model nonlinear trial-level dynamics. Figure 3 reinforces the conclusion that GB offers the best overall predictive accuracy and provides the most reliable trial-level performance across varying metabolic cost profiles.
FIGURE 3

Trial-wise comparison of actual versus predicted metabolic cost across all models. Each subplot shows predicted (red dashed line) and actual (black line) normalized metabolic cost across 100 test trials for a single model. The x-axis represents trial indices normalized to the [0, 1] range to emphasize pattern alignment and model comparison rather than raw trial numbering. The subplots correspond to: (A) Linear Ridge (LR), (B) Polynomial Ridge (PR), (C) Gaussian Process Squared Exponential (GPSE), (D) Gaussian Process Matern 3/2 (GPM), (E) Gaussian Process Absolute Exponential (GPAE), (F) Gaussian Process Rational Quadratic (GPRQ), (G) Support Vector Regression (SVR), (H) Random Forest (RF), and (I) Gradient Boosting (GB). GB (I) exhibited the closest agreement with actual values, accurately tracking the trend and magnitude. RF (H) and GP models (C–F) showed moderate fidelity, whereas LR (A), PR (B), and SVR (G) failed to capture rapid changes or peak variations. These plots emphasize GB’s superior predictive performance and trial-level reliability for metabolic cost estimation. Unlike Figure 2, which summarizes average errors, this figure emphasizes trial-specific fidelity using models trained on the full dataset. Linear and Polynomial Ridge produce flatter predictions and fail to capture trial-level nonlinearities, whereas Gradient Boosting aligns more closely with actual data, underscoring its superior expressiveness.
Although LR and PR achieved relatively low RAEP values (∼0.88%) in the cross-validation analysis (Figure 2), their performance was not considered acceptable for surrogate-based optimization. This is because optimization requires models that capture localized trial-to-trial variations and nonlinear dynamics of the metabolic cost landscape. Figures 3, 4 show that LR and PR produced flatter predictions and featureless landscapes, failing to represent critical nonlinearities between assistance parameters and metabolic cost. The apparent discrepancy between Figures 2, 3 arises from their distinct methodologies: Figure 2 reports averaged RAEP from cross-validation, which masks trial-specific deviations, whereas Figure 3 evaluates trial-level fidelity using models trained on the full dataset (Slade et al., 2022;
FIGURE 4

Predicted metabolic landscapes with overlaid actual data points for each surrogate model. Filled contour plots represent predicted normalized metabolic cost over the assistance parameter space, defined by End Timing (x-axis) and Peak Magnitude (y-axis). Overlaid circles indicate the actual experimental data points used for training. The subplots correspond to: (A) Linear Ridge (LR), (B) Polynomial Ridge (PR), (C) Gaussian Process Squared Exponential (GPSE), (D) Gaussian Process Matern 3/2 (GPM), (E) Gaussian Process Absolute Exponential (GPAE), (F) Gaussian Process Rational Quadratic (GPRQ), (G) Support Vector Regression (SVR), (H) Random Forest (RF), and (I) Gradient Boosting (GB). GB (I) generated the most detailed and responsive cost surface, capturing sharp gradients and nonlinear parameter interactions. RF (H) and GP models (C–F) showed smoother interpolations with moderate spatial resolution. SVR (G) produced more diffuse gradients, while LR (A) and PR (B) failed to reflect meaningful topographic variation. These visualizations support GB’s superior spatial expressiveness and consistency with the actual data distribution.
Figure 4 presents each surrogate model’s predicted metabolic time profiles using filled contour plots, with overlaid actual data points shown as circles. The plots depict each model’s mapping of the normalized assistance parameter space, characterized by Peak Magnitude (y-axis) and End Timing (x-axis), to the corresponding predicted changes in normalized metabolic cost. Notably, GB (Figure 4I) captures sharp transitions and localized cost gradients, showing a highly responsive and detailed cost surface. The filled contours in the GB plot reveal strong differentiation across regions, consistent with the model’s ability to generalize complex, nonlinear interactions between parameters. In contrast, LR (Figure 4A) and PR (Figure 4B) produce relatively flat and featureless landscapes, suggesting limited ability to represent nonlinear cost changes. GP models—GPSE, GPM, GPAE, and GPRQ (Figures 4C–F)—generate smoothly varying surfaces that interpolate well across the space but lack high-frequency response near dense data clusters. This reflects their kernel-driven behavior, which favors continuity over local sensitivity. SVR (Figure 4G) shows a more spread-out prediction pattern with rough gradients, failing to align closely with the actual metabolic cost pattern. RF (Figure 4H) demonstrates improved spatial granularity, particularly near more concentrated regions of the parameter space, though its boundaries remain blocky due to the discrete nature of tree-based predictions. These landscape visualizations reinforce earlier quantitative findings: GB provides the most spatially expressive and data-consistent model, making it the most appropriate choice for surrogate-based optimization of exoskeleton assistance.
3.2 Optimization results
Optimization results are summarized in Table 3. Compared to all other algorithms, GSA reached the lowest normalized metabolic cost (−1.06), indicating the most considerable reduction over the PowerOff baseline. This solution was located at (Peak Magnitude = 0.20) and (End Timing = 0.83), a region identified across multiple high-performing methods. PSO also reached near-optimal cost (−1.00), but with a much lower Mean ARI (0.30 × 10−5), indicating slower convergence despite strong endpoint performance. BO and EBO predicted final costs of −0.999 and −0.990, respectively, with moderate AUC values (BO: 0.32, EBO: 0.27), highlighting efficient early search performance. EBO reached the highest Mean ARI (3.29 × 10−5), suggesting the most rapid cost reduction per iteration. In contrast, CMAES and CE resulted in higher costs (−0.68 and −0.74, respectively) and less efficient convergence (AUC: 0.56 and 0.46). GA produced the highest final cost (0.40), exceeding the baseline, and confirming the weakest optimization performance in this context.
TABLE 3
| Algorithm | Number of evaluations | Mean time (s) | Peak magnitude | End timing | Normalized Metabolic cost | Mean AUC | Mean ARI |
|---|---|---|---|---|---|---|---|
| CMAES | 200.00 | 0.60 | 0.44 | 0.68 | −0.68 | 0.56 | 1.85 × 10−5 |
| BO | 200.00 | 26.01 | 0.12 | 0.80 | −1.00 | 0.32 | 2.32 × 10−5 |
| EBO | 200.00 | 24.01 | 0.19 | 0.82 | −0.99 | 0.27 | 3.29 × 10−5 |
| CE | 200.00 | 0.60 | 0.42 | 0.79 | −0.74 | 0.46 | 2.58 × 10−5 |
| GA | 200.00 | 0.73 | 0.10 | 0.56 | 0.40 | 0.33 | 2.57 × 10−5 |
| GSA | 200.00 | 0.59 | 0.20 | 0.83 | −1.06 | 0.61 | 2.21 × 10−5 |
| PSO | 200.00 | 1.26 | 0.13 | 0.82 | −1.00 | 0.24 | 0.30 × 10−5 |
Optimization results summary. Summary of performance metrics for the seven optimization algorithms integrated with the Gradient Boosting (GB) surrogate model. The table includes: (1) the number of evaluations to convergence, (2) the mean computational time in seconds, (3) the optimal assistance parameters—Peak Magnitude and End Timing—identified by each algorithm, (4) the mean normalized metabolic cost achieved at convergence, (5) the mean area under the convergence curve (AUC) as a measure of optimization efficiency, and (6) the average rate of improvement (ARI) representing convergence speed. Algorithms include Covariance Matrix Adaptation Evolution Strategy (CMAES), Bayesian Optimization (BO), Exploitative Bayesian Optimization (EBO), Cross-Entropy (CE), Genetic Algorithm (GA), Gravitational Search Algorithm (GSA), and Particle Swarm Optimization (PSO). To improve clarity for biomechanics-focused readers, we provide brief interpretations of the key metrics used in this study. The Relative Absolute Error Percentage (RAEP) quantifies how closely the surrogate model predicts metabolic cost relative to experimental ground truth, with lower RAEP reflecting greater predictive accuracy and alignment with physiological outcomes. The Area Under the Convergence Curve (AUC) measures the efficiency of an optimizer by integrating error reduction across iterations; a smaller AUC indicates faster and more reliable convergence toward an optimal assistance profile. The Adjusted Rank Index (ARI) evaluates the consistency and robustness of optimizer performance across repeated simulations, helping to identify stable strategies that are more likely to generalize in practice. The predicted metabolic cost provides surrogate-based estimates of energy expenditure under different assistance profiles, normalized to baseline walking, where lower values suggest potential reductions in user effort. Finally, optimization runtime represents computational latency in simulation rather than biological stabilization time, allowing algorithms to be compared on efficiency while acknowledging that human-in-the-loop experiments are dominated by physiological adaptation timescales.
Figure 5 shows optimization outcomes using the GB model’s convergence trajectories (Figure 5A) and the predicted metabolic pattern (Figure 5B). In Figure 5A, BO, EBO, and PSO converged rapidly within the first 100 evaluations, with EBO showing the most rapid decline, aligning with its high ARI. While ultimately reaching the lowest cost, GSA showed greater variance over time, consistent with its higher AUC (0.61). Figure 5B displays the optimal solutions from all algorithms on the GB-predicted cost surface. Most optima are clustered within a region defined by Peak Magnitude = (0.10–0.20) and End Timing = (0.75–0.85), representing a biomechanically meaningful and metabolically favorable range. This agreement across algorithms validates the surrogate model’s reliability in guiding the search toward physiologically optimal assistance profiles.
FIGURE 5

Optimization convergence and parameter landscape. (A) Convergence trajectories of seven global optimization algorithms over 200 evaluations, using the Gradient Boosting (GB) surrogate model. Algorithms include: Covariance Matrix Adaptation Evolution Strategy (CMAES), Bayesian Optimization (BO), Exploitative Bayesian Optimization (EBO), Cross-Entropy (CE), Genetic Algorithm (GA), Gravitational Search Algorithm (GSA), and Particle Swarm Optimization (PSO). BO, EBO, and PSO reached near-optimal solutions within the first 100 evaluations. GSA ultimately reached the lowest final cost but showed greater variability across iterations. (B) The GB-predicted metabolic cost surface is visualized as a filled contour plot across the assistance parameter space (Peak Magnitude and End Timing). Final optimal solutions from each algorithm are plotted, showing that most solutions converged within a low-cost region between Peak Magnitude 0.10–0.20 and End Timing 0.75–0.85.
Figure 6 summarizes the performance of all optimization algorithms using bar plots for key evaluation metrics. Figure 6A shows the average convergence time. BO and EBO required the longest mean time to converge (26.01 s and 24.01 s, respectively), reflecting the added computational cost of their model-fitting steps. In contrast, CMAES, CE, GA, and GSA ALL converged in less than 1 s, while PSO required a moderate 1.26 s to converge. These runtimes represent computational latency only and do not account for biological stabilization times inherent to human experiments. Figure 6B presents the normalized metabolic cost at optimum. Among all algorithms, GB predicted the largest metabolic reduction, with an optimal normalized metabolic cost of −1.06, corresponding to a 53% predicted reduction compared to the no-assistance baseline. It should be noted that this reduction reflects model-based predictions rather than direct human metabolic measurements. PSO, BO, and EBO converged to similarly low values near −1.00, indicating strong final performance. CE and CMAES reached higher-cost plateaus (−0.74 and −0.68, respectively), while GA performed poorly with a final cost of 0.40, failing to reduce metabolic cost. Figure 6C displays the mean AUC, a measure of optimization efficiency. PSO predicted the lowest AUC (0.24), followed by EBO (0.27) and BO (0.32), indicating compelling early exploration and convergence. In contrast, GSA had the highest AUC (0.61), suggesting slower but ultimately effective convergence. Figure 6D compares the ARI across algorithms. EBO predicted the highest Mean ARI (3.29 × 10−5), reflecting the steepest per-iteration improvement. CE (2.58 × 10−5) and GA (2.57 × 10−5) also demonstrated strong ARI values, while BO and GSA showed moderate improvement rates (2.32 × 10−5 and 2.21 × 10−5, respectively). Despite its substantial final cost, PSO had the lowest ARI (0.30 × 10−5), indicating slower per-step progress.
FIGURE 6

Optimization algorithm performance comparison. Summary of key performance metrics for Covariance Matrix Adaptation Evolution Strategy (CMAES), Bayesian Optimization (BO), Exploitative Bayesian Optimization (EBO), Cross-Entropy (CE), Genetic Algorithm (GA), Gravitational Search Algorithm (GSA), and Particle Swarm Optimization (PSO). (A) Mean time to convergence, highlighting the higher computational cost of BO and EBO relative to other methods. (B) Final normalized metabolic cost predicted by each algorithm, with GSA attaining the lowest value. (C) Mean area under the convergence curve (AUC), where lower values indicate higher optimization efficiency. (D) Average rate of improvement (ARI), representing the steepness of per-iteration cost reduction, with EBO yielding the highest ARI. The error bars reflect variability across repeated optimization runs, providing uncertainty quantification for convergence efficiency and predicted metabolic cost outcomes. To improve clarity for biomechanics-focused readers, we provide brief interpretations of the key metrics used in this study. The Relative Absolute Error Percentage (RAEP) quantifies how closely the surrogate model predicts metabolic cost relative to experimental ground truth, with lower RAEP reflecting greater predictive accuracy and alignment with physiological outcomes. The Area Under the Convergence Curve (AUC) measures the efficiency of an optimizer by integrating error reduction across iterations; a smaller AUC indicates faster and more reliable convergence toward an optimal assistance profile. The Adjusted Rank Index (ARI) evaluates the consistency and robustness of optimizer performance across repeated simulations, helping to identify stable strategies that are more likely to generalize in practice. The predicted metabolic cost provides surrogate-based estimates of energy expenditure under different assistance profiles, normalized to baseline walking, where lower values suggest potential reductions in user effort. Finally, optimization runtime represents computational latency in simulation rather than biological stabilization time, allowing algorithms to be compared on efficiency while acknowledging that human-in-the-loop experiments are dominated by physiological adaptation timescales.
4 Discussion
This study assessed the predictive accuracy of surrogate models and compared the performance of optimization algorithms in identifying metabolically efficient hip exoskeleton assistance settings. It was hypothesized that BO, with its probabilistic acquisition mechanism that strategically balances exploration and exploitation, would surpass heuristic approaches such as PSO, particularly in scenarios constrained by limited evaluation resources. Our findings partially supported this hypothesis. By achieving a 53% metabolic cost reduction within seconds, the proposed simulation-based surrogate modeling and optimization framework significantly reduces experimental burden and supports real-time adaptive control, advancing the deployment of personalized exoskeleton strategies. While BO and EBO demonstrated high convergence efficiency and strong predictive accuracy when coupled with the GB surrogate model, PSO and GSA also showed exceptional performance. Specifically, GSA predicted the lowest predicted normalized metabolic cost (−1.06), and PSO recorded the most efficient convergence (AUC = 0.24). These outcomes suggest that, although BO-based strategies are effective in data-limited conditions, heuristic methods such as PSO and GSA remain highly competitive when paired with robust surrogate models.
4.1 Modeling the metabolic landscape
Consistent with prior efforts to simulate HIL optimization using surrogate models for ankle exoskeletons (
Although RAEP is a standard metric for evaluating surrogate model accuracy, in this study, it yielded uniformly low values across all models, making it less informative for distinguishing performance differences among optimizers. For this reason, RAEP should be interpreted cautiously and primarily as a measure of overall model fit, while metrics such as AUC and ARI provide more meaningful insight into optimizer efficiency and convergence behavior.
While the surrogate landscape provides a computationally efficient means to test optimization strategies, it remains an approximation of real physiology. As such, the reported metabolic reductions represent model-based predictions rather than empirical measurements. Future validation in live HIL trials is required to confirm the translational relevance of these findings. Uncertainty was evaluated using multiple complementary approaches. Gaussian Process models provided predictive confidence intervals, while ensemble methods (GB, RF) allowed assessment of stability via tree variance. Additionally, variability across 500 cross-validation splits highlighted sensitivity to training/test partitioning. Together, these measures provided insight into model robustness and the reliability of surrogate predictions (Slade et al., 2022;
4.2 Simulating HIL optimization
This study advances simulation-based HIL optimization by evaluating multiple global algorithms for identifying individualized hip exoskeleton assistance parameters. The optimization framework yielded a metabolic cost reduction of up to 53%, with GSA achieving the lowest normalized metabolic cost (−1.06) at a Peak Magnitude of 0.20 and End Timing of 0.83. This assistance timing aligns with late stance, coinciding with peak activity of the hip extensors, and is supported by prior biomechanical studies emphasizing late-phase torque application to reduce muscular demand (
Our findings partially diverge from Kutulakos and Slade (
The broad low-cost region identified by the surrogate landscape (Peak Magnitude = 0.10–0.20, End Timing = 0.75–0.85; Figure 5B) suggests that diverse parameter sets may yield similar benefits, offering greater flexibility for adaptive controllers than the narrow optima often observed in experimental HIL studies (Zhang et al., 2017;
To ground our parameterization biomechanically, the two torque parameters studied—Peak Magnitude and End Timing—were selected because they represent the most influential biomechanical factors in hip exoskeleton assistance. Peak Magnitude defines the level of external torque applied to the hip extensors during stance, directly influencing muscle activation and joint loading, while End Timing determines when assistance is withdrawn, shaping the transition into swing and neuromuscular adaptation. Prior experimental studies have shown that both magnitude and timing critically modulate metabolic cost and gait stability, supporting their selection as physiologically meaningful variables (
Regarding the augmented dataset, interpolation and controlled perturbations were used to expand the input space while preserving biomechanical plausibility, ensuring that torque profiles remained within safe and physiologically realistic ranges observed in prior exoskeleton trials (Slade et al., 2018; Slade et al., 2022;
For optimization algorithms, we included a diverse set spanning evolutionary, swarm-based, and Bayesian families to evaluate both exploration and exploitation strategies in a surrogate-based HIL context (
Ultimately, selecting the most appropriate optimization algorithm depends on the specific application goals and targeted population (
Similar simulation-first approaches have been applied in other engineering domains, where surrogate modeling and optimization have effectively reduced experimental costs and accelerated iteration cycles. For example, sustainable additive manufacturing has leveraged computational optimization to minimize resource usage and emissions (
Integrating biomechanics and motor adaptation perspectives further underscores the potential of surrogate-based frameworks to enhance exoskeleton control. Neuromuscular adaptation during exoskeleton use reflects gait plasticity, whereby users adjust stride patterns and muscle recruitment in response to assistance, often achieving improved energy efficiency over repeated sessions (
In practical applications, surrogate models trained on data from healthy individuals could provide initial estimates of optimal assistance parameters for new users. These predictions could then be refined using limited personalized trials, enabling efficient customization of hip exoskeleton settings for clinical or real-world deployment. This simulation-based framework provides a foundation for translational application by identifying which optimization algorithms are most promising for HIL trials. In practice, surrogate-based insights can narrow the search space and initialize parameter settings, reducing the number of physical iterations required. The next step is to validate these algorithms in experimental HIL studies with the same hip exoskeleton device, where real-time metabolic feedback, user-specific adaptation, and fatigue effects can be directly assessed. Ultimately, this approach enables a more efficient pathway from simulation to clinical deployment, where optimization strategies can be tailored to patients and workers in rehabilitation and occupational settings.
4.3 Limitations
Although the surrogate-based optimization methods demonstrated promising performance, several limitations should be acknowledged. First, based on simulations run on a standard laptop, the reported computation times for each optimization algorithm may not directly translate to realistic experimental scenarios (
It is important to clarify that the reported runtimes (e.g., BO: 26 s) represent computational latency only and do not reflect the dominant biological stabilization periods required in real HIL experiments, which often extend to several minutes per condition and can accumulate to ∼2 h for a full optimization session. While the proposed surrogate-based framework offers substantial potential to reduce this experimental burden, its real-world speed remains constrained by participant fatigue and adaptation. As a limitation, future work should explicitly validate the true time savings in live HIL optimization experiments with the same exoskeleton system to confirm translational feasibility. While uncertainty was partially quantified through Gaussian Process confidence intervals, ensemble variance, and cross-validation variability, we acknowledge that real-world variability—particularly in clinical populations—may exceed model-based estimates. Future work should expand uncertainty quantification to better capture patient-specific unpredictability. While the present framework provides simulation-based predictions of optimal assistance patterns, these results have not yet been validated in real human-in-the-loop trials. Real-world experiments will be necessary to confirm the predicted metabolic cost reductions, capture adaptation and fatigue effects, and ensure clinical and translational relevance. The addition of error bars in Figure 6 helps convey variability in simulated outcomes, but physical trials remain the definitive step to establish robustness and generalizability. Our augmentation strategy perturbed input parameters to enrich surrogate training, which assumes that trial-to-trial variability in assistance settings can be represented as Gaussian noise. While this improved robustness, it does not directly model physiological variability or device measurement error, and future studies should examine whether input perturbations adequately reflect real-world variability in exoskeleton assistance.
Since our analysis relied on previously collected experimental data (
The surrogate model was trained on pooled data from healthy adults, which may not fully capture inter-individual variability or the unique metabolic landscapes of clinical populations. Gait variability influenced by factors such as pathology, age, or fitness may amplify errors in optimization, as clinical users often adapt differently or require extended habituation (
Furthermore, this study’s optimization results were derived using a limited dataset from 10 healthy adults. While this cohort offers a proof-of-concept for healthy populations, it restricts the generalizability of the findings to broader user groups such as older adults, clinical populations, or individuals with gait impairments (
5 Conclusion
This study introduced a surrogate-based HIL optimization framework for personalizing hip exoskeleton assistance. Among the evaluated ML regressors, GB demonstrated the highest predictive accuracy (RAEP = 0.66%). When paired with global optimizers, GSA predicted the lowest normalized metabolic cost (−1.06), while PSO and EBO exhibited superior convergence efficiency based on AUC and ARI metrics. Beyond individual algorithm performance, this framework approach offers a generalized methodology for screening optimization algorithms and hyperparameters before any human testing. Researchers developing new exoskeletons or assistive devices can gather a small set of assistance trials, fit a surrogate model, and run virtual HIL optimizations to identify the algorithms most likely to succeed in practice. In the clinic, the same surrogate can guide a brief calibration session in which the optimizer samples a few gait cycles and then recommends patient-specific peak-torque magnitudes and timing parameters, delivering a custom assistance profile in minutes rather than hours of metabolic titration. This process can significantly reduce experimental burden, enhance reproducibility, and streamline the deployment of personalized assistive strategies. Looking forward, this framework could be embedded into real-time adaptive controllers, enabling assistance profiles to update dynamically as patients adapt or as clinical needs evolve. Future research should validate these simulation-informed strategies in both healthy and clinical populations to ensure safety and translational viability. Ultimately, these steps will accelerate the deployment of exoskeleton technologies across rehabilitation, occupational, and performance domains, ensuring that optimization strategies remain responsive to diverse user populations. Beyond exoskeleton research, the methodological principles of surrogate-based optimization can be extended to other biomechanical and engineering applications where system-level sustainability and efficiency are critical. Similar strategies have been successfully applied in domains such as sustainable additive manufacturing (
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
AMG: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing. IIP: Validation, Visualization, Writing – review and editing. SAM: Data curation, Funding acquisition, Validation, Writing – review and editing. FF: Data curation, Validation, Visualization, Writing – original draft, Writing – review and editing.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. American Heart Association (25CDA1454074). National Institutes of Health (P20GM109090, R01HD090333, R01AG077803, and R01AG062198). U.S. Department of Veterans Affairs Rehabilitation Research and Development Service (I01RX000604 and I01RX003266).
Acknowledgments
We thank Philippe Malcolm for his insightful advice.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AlaiaE. B.DhahriS.NaifarO. (2025). A gradient-based optimization algorithm for optimal control problems with general conformable fractional derivatives. IEEE Access13, 140270–140281. 10.1109/ACCESS.2025.3595958
2
AntonellisP.GalleS.De ClercqD.MalcolmP. (2018). Altering gait variability with an ankle exoskeleton. PLoS One13, e0205088. 10.1371/journal.pone.0205088
3
AntonellisP.Mohammadzadeh GonabadiA.MyersS. A.PipinosI. I.MalcolmP. (2022). Metabolically efficient walking assistance using optimized timed forces at the waist. Sci. Robot.7, eabh1925. 10.1126/scirobotics.abh1925
4
AronesM. M.ShourijehM. S.PattenC.FreglyB. J. (2020). Musculoskeletal model personalization affects metabolic cost estimates for walking. Front. Bioeng. Biotechnol.8, 588925. 10.3389/fbioe.2020.588925
5
Bartz-BeielsteinT.ChiarandiniM.PaqueteL.PreussM. (2010). in Experimental methods for the analysis of optimization algorithms. Editors Bartz-BeielsteinT.ChiarandiniM.PaqueteL.PreussM.1st Edn (Berlin, Heidelberg: Springer Berlin Heidelberg). 10.1007/978-3-642-02538-9
6
BaudR.ManzooriA. R.IjspeertA.BouriM. (2021). Review of control strategies for lower-limb exoskeletons to assist gait. J. Neuroeng. Rehabil.18, 119. 10.1186/s12984-021-00906-3
7
BreimanL. (2001). Random forests. Mach. Learn.45, 5–32. 10.1023/A:1010933404324
8
BryanG. M.FranksP. W.SongS.VoloshinaA. S.ReyesR.O’DonovanM. P.et al (2021). Optimized hip-knee-ankle exoskeleton assistance at a range of walking speeds. J. Neuroeng. Rehabil.18, 152. 10.1186/s12984-021-00943-y
9
ChangY.KangJ.JeongB.KimG.LimB.ChoiB.et al (2023). Verification of industrial worker walking efficiency with wearable hip exoskeleton. Appl. Sci.13, 12609. 10.3390/app132312609
10
CharetteC.DéryJ.BlanchetteA. K.FaureC.RouthierF.BouyerL. J.et al (2023). A systematic review of the determinants of implementation of a locomotor training program using a powered exoskeleton for individuals with a spinal cord injury. Clin. Rehabil.37, 1119–1138. 10.1177/02692155231164092
11
CoelloC. A. C.PulidoG. T.LechugaM. S. (2004). Particle swarm optimization, 8, 256–279.
12
Das GuptaS.BobbertM. F.KistemakerD. A. (2019). The metabolic cost of walking in healthy young and older adults – a systematic review and Meta analysis. Sci. Rep.9, 9956. 10.1038/s41598-019-45602-4
13
de LoozeM. P.BoschT.KrauseF.StadlerK. S.O’SullivanL. W. (2016). Exoskeletons for industrial application and their potential effects on physical work load. Ergonomics59, 671–681. 10.1080/00140139.2015.1081988
14
DengL.-Y. (2006). The cross-entropy method: a unified approach to combinatorial optimization, Monte-Carlo simulation, and machine learning. Technometrics48, 147–148. 10.1198/tech.2006.s353
15
DesplenterT.TrejosA. (2018). Evaluating muscle activation models for elbow motion estimation. Sensors18, 1004. 10.3390/s18041004
16
DingY.KimM.KuindersmaS.WalshC. J. (2018). Human-in-the-loop optimization of hip assistance with a soft exosuit during walking. Sci. Robot.3, eaar5438–eaar5439. 10.1126/scirobotics.aar5438
17
DzewaltowskiA. C.AntonellisP.Mohammadzadeh GonabadiA.SongS.MalcolmP. (2024). Perturbation-based estimation of within-stride cycle metabolic cost. J. Neuroeng. Rehabil.21, 131. 10.1186/s12984-024-01424-8
18
EchevesteS.BhounsuleP. A. (2025). EMG-Based human-in-the loop bayesian optimization to assist free leg swinging. 10.20944/preprints202501.1346.v1
19
EdwardsD. J.ForrestG.CortesM.WeightmanM. M.SadowskyC.ChangS.-H. H.et al (2022). Walking improvement in chronic incomplete spinal cord injury with exoskeleton robotic training (WISE): a randomized controlled trial. Spinal Cord.60, 522–532. 10.1038/s41393-022-00751-8
20
FallahtaftiF.Mohammadzadeh GonabadiA.SamsonK.YentesJ. M. (2021). Margin of stability may be larger and less variable during treadmill walking versus overground. Biomech.1, 118–130. 10.3390/biomechanics1010009
21
FarrisD. J.HarrisD. J.RiceH. M.CampbellJ.WeareA.RisiusD.et al (2023). A systematic literature review of evidence for the use of assistive exoskeletons in defence and security use cases. Ergonomics66, 61–87. 10.1080/00140139.2022.2059106
22
FirouziV.SeyfarthA.SongS.von StrykO.Ahmad SharbafiM. (2025). Biomechanical models in the lower-limb exoskeletons development: a review. J. Neuroeng. Rehabil.22, 12. 10.1186/s12984-025-01556-5
23
FoxS.ArankoO.HeilalaJ.VahalaP. (2019). Exoskeletons. J. Manuf. Technol. Manag.31, 1261–1280. 10.1108/JMTM-01-2019-0023
24
FranksP. W.BryanG. M.MartinR. M.ReyesR.LakmazaheriA. C.CollinsS. H. (2021). Comparing optimized exoskeleton assistance of the hip, knee, and ankle in single and multi-joint configurations. Wearable Technol.2, e16. 10.1017/wtc.2021.14
25
FriedmanJ. H. (2001). Greedy function approximation: a gradient boosting machine. Ann. Stat.29. 10.1214/aos/1013203451
26
GonabadiA. M. (2016). 3D truss design and optimization using optimization methods.
27
GonabadiA. M.AntonellisP.MalcolmP. (2020). A system for simple robotic walking assistance with linear impulses at the center of mass. IEEE Trans. Neural Syst. Rehabil. Eng.28, 1353–1362. 10.1109/tnsre.2020.2988619
28
GonabadiA. M.ConnellyE.WilliamsN.MasseyJ.SolsrudA.JanovecD.et al (2025). Prediction of overall sleep score outcomes in patients with postacute sequelae of COVID-19 using smartwatch data: an artificial neural network approach. Arch. Phys. Med. Rehabil.106, e158. 10.1016/j.apmr.2025.01.408
29
HansenN.OstermeierA. (2001). Completely derandomized self-adaptation in evolution strategies. Evol. Comput.9, 159–195. 10.1162/106365601750190398
30
HastieT.TibshiraniR.FriedmanJ. (2009). The elements of statistical learning. New York, NY: Springer New York. 10.1007/978-0-387-84858-7
31
HoerlA. E.KennardR. W. (2000). Ridge regression: biased estimation for nonorthogonal problems. Technometrics42, 80. 10.2307/1271436
32
HollandJ. H. (1992). Adaptation in natural and artificial systems. The MIT Press. 10.7551/mitpress/1090.001.0001
33
HsuS.-H.ChangchengC.LeeH.-J.ChenC.-T. (2021). Design and implementation of a robotic hip exoskeleton for gait rehabilitation. Actuators10, 212. 10.3390/act10090212
34
JiryaeiZ.AlvarA. A.BaniM. A.VahediM.JafarpishehA. S.RazfarN. (2021). Development and feasibility of a soft pneumatic-robotic glove to assist impaired hand function in quadriplegia patients: a pilot study. J. Bodyw. Mov. Ther.27, 731–736. 10.1016/j.jbmt.2021.03.012
35
KollerJ. R.H GatesD.P FerrisD.David RemyC. (2016). “Body-in-the-Loop optimization of assistive robotic devices: a validation study,” in Robotics: science and systems XIIAnn Arbor, MI: Robotics: Science and Systems Foundation. Available online at: https://www.roboticsproceedings.org/rss12/p07.pdf.
36
KutulakosZ.SladeP. (2024). Simulating human-in-the-loop optimization of exoskeleton assistance to compare optimization algorithm performance. 10.1101/2024.04.05.587982
37
KuyuY. C.VatanseverF. (2019). “A comparative study of the state-of-the-art algorithms on multi-objective problems using performance metrics,” in 2019 11th international conference on electrical and electronics engineering (ELECO) (IEEE), 905–910. 10.23919/ELECO47770.2019.8990599
38
LakmazaheriA.CollinsS. H. (2025). Biofeedback speeds adaptation to exoskeleton gait assistance. 10.1101/2025.06.21.660857
39
LakmazaheriA.SongS.VuongB. B.BisknerB.KadoD. M.CollinsS. H. (2024). Optimizing exoskeleton assistance to improve walking speed and energy economy for older adults. J. Neuroeng. Rehabil.21, 1. 10.1186/s12984-023-01287-5
40
LeeG.KimJ.PanizzoloF. A.ZhouY. M.BakerL. M.GalianaI.et al (2017). Reducing the metabolic cost of running with a tethered soft exosuit. Sci. Robot.2, eaan6708. 10.1126/scirobotics.aan6708
41
LeeK.-J.NamY.-G.YuJ.-H.KimJ.-S. (2025). Effect of wearable exoskeleton robots on muscle activation and gait parameters on a treadmill: a randomized controlled trial. Healthcare13, 700. 10.3390/healthcare13070700
42
LeibmanD.ChoiH. (2025). Going beyond the mean in examining the effects of exoskeleton use on motor and attentional task performance. Appl. Ergon.129, 104567. 10.1016/j.apergo.2025.104567
43
LinW.DongH.GaoY.WangW.LongY.HeL.et al (2025). A systematic review of locomotion assistance exoskeletons: prototype development and technical challenges. Technologies13, 69. 10.3390/technologies13020069
44
MaY.LiuD.YanZ.YuL.GuiL.YangC.et al (2024). Optimizing exoskeleton assistance: muscle synergy-based actuation for personalized hip exoskeleton control. Actuators13, 54. 10.3390/act13020054
45
MalcolmP.GalleS.De ClercqD. (2017). Fast exoskeleton optimization. Sci. 80356, 1230–1231. 10.1126/science.aan5367
46
MohammadzadehA.GhoddoosianA.Nouri DamghaniM. (2011). Balancing of the flexible rotors with particle swarm optimization method. Int. Rev. Mech. Eng.5 (3), 490–496. Available online at: https://www.praiseworthyprize.org/jsm/?journal=ireme#:~:text=IREME%20also%20publishes%20letters%20to,and%20publication%20is%2021%20days
47
Mohammadzadeh GonabadiA.FallahtaftiF. (2025). Gait stability under hip exoskeleton assistance: a phase-dependent analysis using gait tube methodology. Appl. Sci.15, 7530. 10.3390/app15137530
48
Mohammadzadeh GonabadiA.MohebbiM.Sohan AjiniA. (2017a). Topology and weight optimization of a 3D truss by numerical Method. Mech. Mater. Sci. Eng.10.2412/mmse.52.11.596
49
Mohammadzadeh GonabadiA.MohebbiM.Sohan AjiniA.GonabadiA. M.MohebbiM.AjiniA. S. (2017b). The topology and weight optimization of a truss using imperialist competitive algorithm (ICA). Mech. Mater. Sci. Eng.10. 10.2412/mmse.33.83.364
50
Mohammadzadeh GonabadiA.AntonellisP.MalcolmP. (2020). Differences between joint-space and musculoskeletal estimations of metabolic rate time profiles. PLOS Comput. Biol.16, e1008280. 10.1371/journal.pcbi.1008280
51
Mohammadzadeh GonabadiA.AntonellisP.DzewaltowskiA. C.MyersS. A.PipinosI. I.MalcolmP. (2024a). Design and evaluation of a bilateral semi-rigid exoskeleton to assist hip motion. Biomimetics9, 211. 10.3390/biomimetics9040211
52
Mohammadzadeh GonabadiA.FallahtaftiF.AntonellisP.PipinosI. I.MyersS. A. (2024b). Ground reaction forces and joint moments predict metabolic cost in physical performance: harnessing the power of artificial neural networks. Appl. Sci.14, 5210. 10.3390/app14125210
53
Mohammadzadeh GonabadiA.FallahtaftiF.BurnfieldJ. M. (2024c). How gait nonlinearities in individuals without known pathology describe metabolic cost during walking using artificial neural network and multiple linear regression. Appl. Sci.14, 11026. 10.3390/app142311026
54
MonteiroS.FigueiredoJ.FonsecaP.Vilas-BoasJ. P.SantosC. P. (2024). Human-in-the-Loop optimization of knee exoskeleton assistance for minimizing user’s metabolic and muscular effort. Sensors24, 3305. 10.3390/s24113305
55
MusichS.WangS. S.RuizJ.HawkinsK.WickerE. (2018). The impact of mobility limitations on health outcomes among older adults. Geriatr. Nurs. (Minneap).39, 162–169. 10.1016/j.gerinurse.2017.08.002
56
MyungheeK.DingY.MalcolmP.SpeeckaertJ.SiviyC. J. C.WalshC. J.et al (2017). Human-in-the-loop Bayesian optimization of wearable device parameters. PLoS One12, e0184054. 10.1371/journal.pone.0184054
57
NaifarO. (2025). Tempered fractional gradient descent: theory, algorithms, and robust learning applications. Neural Netw.193, 108005. 10.1016/j.neunet.2025.108005
58
OkoroC. A.HollisN. D.CyrusA. C.Griffin-BlakeS. (2018). Prevalence of disabilities and health care access by disability status and type among adults — united States, 2016. MMWR. Morb. Mortal. Wkly. Rep.67, 882–887. 10.15585/mmwr.mm6732a3
59
OladunniO. J.LeeC. K. M.IbrahimI. D.OlanrewajuO. A. (2025). Advances in sustainable additive manufacturing: a systematic review for construction industry to mitigate greenhouse gas emissions. Front. Built Environ.11, 1535626. 10.3389/fbuil.2025.1535626
60
PengZ.LuoR.HuangR.YuT.HuJ.ShiK.et al (2020). Data-driven optimal assistance control of a lower limb exoskeleton for hemiplegic patients. Front. Neurorobot.14, 37. 10.3389/fnbot.2020.00037
61
PoggenseeK. L.CollinsS. H. (2021). How adaptation, training, and customization contribute to benefits from exoskeleton assistance. Sci. Robot.6, eabf1078. 10.1126/scirobotics.abf1078
62
RashediE.Nezamabadi-pourH.SaryazdiS. (2009). GSA: a gravitational search algorithm. Inf. Sci. (Ny)179, 2232–2248. 10.1016/j.ins.2009.03.004
63
RasmussenC. E. (2004). “Gaussian processes in machine learning,” 63–71. 10.1007/978-3-540-28650-9_4
64
RayssiguieE.ErdenM. S. (2022). A review of exoskeletons considering nurses. Sensors22, 7035. 10.3390/s22187035
65
Rodríguez-FernándezA.Lobo-PratJ.Font-LlagunesJ. M. (2021). Systematic review on wearable lower-limb exoskeletons for gait training in neuromuscular impairments. J. Neuroeng. Rehabil.18, 22. 10.1186/s12984-021-00815-5
66
SadoT.MotzZ.YentesJ. M.MukherjeeM. (2022). Passive exoskeleton-assisted gait shows a unique interlimb coordination signature without restricting regular walking. Front. Physiol.13, 916185. 10.3389/fphys.2022.916185
67
SanjeeviN. S. S.SinghY.VashistaV. (2021). Recent advances in lower-extremity exoskeletons in promoting performance restoration. Curr. Opin. Biomed. Eng.20, 100338. 10.1016/j.cobme.2021.100338
68
ScherbD.WartzackS.MiehlingJ. (2023). Modelling the interaction between wearable assistive devices and digital human models—A systematic review. Front. Bioeng. Biotechnol.10, 1044275. 10.3389/fbioe.2022.1044275
69
SethA.HicksJ. L.UchidaT. K.HabibA.DembiaC. L.DunneJ. J.et al (2018). OpenSim: simulating musculoskeletal dynamics and neuromuscular control to study human and animal movement. PLoS Comput. Biol.14, e1006223. 10.1371/journal.pcbi.1006223
70
ShepertyckyM.BurtonS.DicksonA.LiuY.-F.LiQ. (2021). Removing energy with an exoskeleton reduces the metabolic cost of walking. Sci. 80372, 957–960. 10.1126/science.aba9947
71
SladeP.TroutmanR.KochenderferM. J.CollinsS. H.DelpS. L. (2018). Rapid energy expenditure estimation for assisted and inclined loaded walking. bioRxiv16, 401836. 10.1101/401836
72
SladeP.KochenderferM. J.DelpS. L.CollinsS. H. (2022). Personalizing exoskeleton assistance while walking in the real world. Nature610, 277–282. 10.1038/s41586-022-05191-1
73
SmolaA. J.SchölkopfB. (2004). A tutorial on support vector regression. Stat. Comput.14, 199–222. 10.1023/B:STCO.0000035301.49549.88
74
SnoekJ.LarochelleH.AdamsR. P. (2012). Practical bayesian optimization of machine learning algorithms. Available online at: http://arxiv.org/abs/1206.2944.
75
SreenivasaM.MillardM.MannsP.MombaurK. (2017). “Optimizing wearable assistive devices with neuromuscular models and optimal control,” 627–632. 10.1007/978-3-319-46669-9_103
76
TyagiN.BhargavaP.AhlawatA. (2024). A comparative analysis of genetic algorithms, particle swarm optimization, and biogeography-based optimization for social media influencer optimization. 10.21203/rs.3.rs-4663399/v1
77
WangW.ChenJ.DingJ.ZhangJ.LiuJ. (2022). Improving walking economy with an ankle exoskeleton prior to human-in-the-loop optimization. Front. Neurorobot.15, 797147. 10.3389/fnbot.2021.797147
78
XuZ.LeeC. K. M.WongC.-N. (2025). A novel fault diagnosis method based on deep stable learning for bearings with imbalanced data samples. Expert Syst. Appl.281, 127634. 10.1016/j.eswa.2025.127634
79
YoungA. J.FerrisD. P. (2017). State of the art and future directions for lower limb robotic exoskeletons. IEEE Trans. Neural Syst. Rehabil. Eng.25, 171–182. 10.1109/TNSRE.2016.2521160
80
ZhangJ.FiersP.WitteK. A.JacksonR. W.PoggenseeK. L.AtkesonC. G.et al (2017). Human-in-the-loop optimization of exoskeleton assistance during walking. Sci. 80356, 1280–1284. 10.1126/science.aal5054
81
ZhuF.KernM.FowkesE.AfzalT.Contreras-VidalJ.-L.FranciscoG. E.et al (2021). Effects of an exoskeleton-assisted gait training on post-stroke lower-limb muscle coordination. J. Neural Eng.18, 046039. 10.1088/1741-2552/abf0d5
Summary
Keywords
hip exoskeleton, machine learning, human-in-the-loop optimization, metabolic cost, personalized wearable robotic control, surrogate modeling, gait optimization, biomechanics
Citation
Mohammadzadeh Gonabadi A, Pipinos II, Myers SA and Fallahtafti F (2025) Optimizing hip exoskeleton assistance pattern based on machine learning and simulation algorithms: a personalized approach to metabolic cost reduction. Front. Robot. AI 12:1669600. doi: 10.3389/frobt.2025.1669600
Received
20 July 2025
Revised
26 August 2025
Accepted
09 September 2025
Published
24 September 2025
Volume
12 - 2025
Edited by
Jungwon Yoon, Gwangju Institute of Science and Technology, Republic of Korea
Reviewed by
Naifar Omar, National Engineering School of Sfax, Tunisia
Oluwole Joseph Oladunni, Durban University of Technology, South Africa
Updates

Check for updates
Copyright
© 2025 Mohammadzadeh Gonabadi, Pipinos, Myers and Fallahtafti.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Arash Mohammadzadeh Gonabadi, amgonabadi@nebraska.edu, amgonabadi@unomaha.edu, agonabadi@madonna.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.